While competitors like United and Aetna are prioritizing margins in a tough Medicare Advantage market, Humana is aggressively pursuing growth. This is a high-risk gamble, as new members are typically unprofitable in their first year. The strategy relies on a favorable, and uncertain, future change in government reimbursement rates.
Related Insights
The new Medicare 'Access' code for AI in chronic care is priced too low to be profitable if humans are kept in the loop. This clever incentive design forces providers to adopt genuine AI-driven leverage rather than simply relabeling human effort, a first for healthcare technology.
Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.
By allowing insurance companies to price plans based on biometric data (blood pressure, fitness), you create powerful financial incentives for people to improve their health. This moves beyond abstract advice and makes diet and exercise a direct factor in personal finance, driving real behavioral change.
When introducing a disruptive model, potential partners are hesitant to be the first adopter due to perceived risk. The strategy is to start with small, persistent efforts, normalizing the behavior until the advantages become undeniable. Innovation requires a patient strategy to overcome initial industry inertia.
High customer concentration risk is mitigated during hypergrowth phases. When customers are focused on speed and market capture, they prioritize effectiveness over efficiency. This provides a window for suppliers to extract high margins, as customers don't have the time or focus to optimize costs or build in-house alternatives.
While digital advertising constitutes 75% of spend in the general economy, it's only about half that in healthcare. This lag, driven by an entrenched reliance on in-person sales reps, creates a long-term secular tailwind for platforms like Doximity as the industry inevitably shifts its marketing budget online.
![Doximity: The Hub of Healthcare - [Business Breakdowns, EP.236] thumbnail](https://megaphone.imgix.net/podcasts/8c0a2a5a-d167-11f0-a7b9-3f57504a8cb8/image/02ea26ff0b721939d29f31ed5fa60266.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress)
To fund crucial investments in wages, prices, and e-commerce, Walmart's leadership, with board support, intentionally reduced its operating income from over 6% to just over 4%. This shareholder-funded investment was a deliberate, multi-year strategy to future-proof the business.
Rapid sales growth creates a powerful "winning" culture that boosts morale and attracts talent. However, as seen with Zenefits, this positive momentum can obscure significant underlying operational or ethical issues. This makes hyper-growth a double-edged sword that leaders must manage carefully.
Government subsidies within healthcare systems like the ACA create a perverse incentive for providers and insurers to inflate prices. This triggers a toxic flywheel: higher costs demand more subsidies, which in turn fuel further price hikes, making the underlying problem of affordability worse over time.
